Revvity, Inc. (NYSE:RVTY) Given Average Rating of “Moderate Buy” by Brokerages

Revvity, Inc. (NYSE:RVTY) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $118.91.

A number of equities research analysts recently issued reports on the stock. Raymond James upped their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. UBS Group cut shares of Revvity from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and upped their price objective for the stock from $88.00 to $125.00 in a report on Thursday, January 4th. Wells Fargo & Company assumed coverage on shares of Revvity in a report on Tuesday, December 19th. They issued an “equal weight” rating and a $95.00 price objective for the company. Finally, Wolfe Research assumed coverage on shares of Revvity in a report on Wednesday, December 13th. They issued a “peer perform” rating for the company.

Insider Buying and Selling at Revvity

In related news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares in the company, valued at $9,677,288.28. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.60% of the company’s stock.

Institutional Investors Weigh In On Revvity

Several hedge funds have recently made changes to their positions in RVTY. Vanguard Group Inc. acquired a new position in Revvity in the third quarter worth about $1,579,487,000. Capital Research Global Investors acquired a new position in Revvity in the fourth quarter worth about $838,080,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Revvity in the fourth quarter worth about $188,368,000. Norges Bank acquired a new position in Revvity in the fourth quarter worth about $129,483,000. Finally, Northern Trust Corp acquired a new position in Revvity in the fourth quarter worth about $127,401,000. Institutional investors own 86.65% of the company’s stock.

Revvity Trading Up 1.9 %

NYSE RVTY opened at $105.41 on Thursday. Revvity has a 1-year low of $79.50 and a 1-year high of $139.04. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $13.02 billion, a PE ratio of 19.17, a price-to-earnings-growth ratio of 2.68 and a beta of 1.10. The firm’s fifty day simple moving average is $105.80 and its 200-day simple moving average is $102.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. Revvity had a net margin of 25.20% and a return on equity of 7.41%. The business had revenue of $695.90 million for the quarter. As a group, sell-side analysts anticipate that Revvity will post 4.65 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Thursday, April 18th. Revvity’s dividend payout ratio (DPR) is 5.09%.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.